Citations

Clear

2 citation(s) found for "Sharma, Shalini".

PET Imaging of Osteomyelitis with [68Ga]Ga-BP
Pandey, Mukesh K., Bansal, Aditya, Sharma, Shalini, Karau, Melissa J. , Raval, Yash S. , Broski, S. M., Patel, Robin , Nathan, Mark, Lowe, Val J., Pandey, Mukesh K. , Broski, Stephen M. , Patel, Robin , Broski, Stephen M , Pandey, Mukesh K , Raval, Yash S. , Bansal, Aditya , Lowe, Val J. , Karau, Melissa

Mayo Clinic

Chemical & Biomedical Imaging | June 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1021/cbmi.6c00082 | PMID 42953237 Get It

Abstract A low-cost, easy-to-adopt noninvasive imaging modality for differentiating bacterial infection from inflammation is desirable to accurately diagnose bacterial infections. Herein, a bacteria-specific PET probe, [68Ga]Ga-BP, was developed and evaluated in rat models of foreign body-associated osteomyelitis induced by methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, and Klebsiella pneumoniae and was directly compared with sterile inflammation and uninstrumented uninfected controls. [68Ga]Ga-BP-based imaging of MRSA-infected tibiae was also compared to [68Ga]Ga-citrate and [18F]FDG. After iron depletion, dynamic PET/CT imaging was performed at 15–120 min postinjection of radiotracers, followed by assessment of ex vivo biodistribution. [68Ga]Ga-BP successfully detected tibial infection and demonstrated >6-fold higher uptake in infected tibiae with all three bacterial species versus contralateral tibiae via PET imaging. [68Ga]Ga-BP outperformed [68Ga]Ga-citrate and [18F]FDG in identifying MRSA infection. [68Ga]Ga-BP represents a promising, noninvasive PET imaging agent for direct bacterial detection and bacterial infection treatment monitoring.
Radiometals in Imaging and Therapy: Highlighting Two Decades of Research
Sharma, Shalini , Pandey, Mukesh K. , Pandey, Mukesh K

Mayo Clinic

Pharmaceuticals | October 14, 2023 | Volume: 16 | Issue: 10 | Pages: 1460

10.3390/ph16101460 | PMID 37895931 Get It

The present article highlights the important progress made in the last two decades in the fields of molecular imaging and radionuclide therapy. Advancements in radiometal-based positron emission tomography, single photon emission computerized tomography, and radionuclide therapy are illustrated in terms of their production routes and ease of radiolabeling. Applications in clinical diagnostic and radionuclide therapy are considered, including human studies under clinical trials; their current stages of clinical translations and findings are summarized. Because the metalloid astatine is used for imaging and radionuclide therapy, it is included in this review. In regard to radionuclide therapy, both beta-minus (β−) and alpha (α)-emitting radionuclides are discussed by highlighting their production routes, targeted radiopharmaceuticals, and current clinical translation stage.